The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advan ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion ...
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
Just over five years ago I was diagnosed with restless legs syndrome – my symptoms were apparently ‘typical’. The neurologist ...
Medpage Today on MSN5d
Continuous Parkinson's Disease Therapy Wins FDA NodAbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...
Tuesday, Sept. 24, former Green Bay Packer and NFL Hall of Fame quarterback Brett Favre testified before Congress. Favre was ...
Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated ...
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback